Keywords: ma, gtc, bio, atryn, goes, leo, firm

MA for GTC Bio's ATryn goes to Leo

Article | 08 January 2007

Print This

US firm GTC Biotherapeutics says that the market authorization of ATryn for the prophylaxis of venous thromboembolism in surgery of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in